Cargando…
The future of immune checkpoint combinations with tumor-targeted small molecule drugs
Immune-checkpoint blockade (ICB) has transformed the landscape of cancer treatment. However, there is much to understand around refractory or acquired resistance in patients in order to utilize ICB therapy to its full potential. In this perspective article, we discuss the opportunities and challenge...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Portland Press Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726049/ https://www.ncbi.nlm.nih.gov/pubmed/34196724 http://dx.doi.org/10.1042/ETLS20210064 |